CURX Curanex Pharmaceuticals Inc

CIK 0002025942 10 ready 8-Ks latest May 14, 2026, 9:15 AM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 10

Latest filing May 14, 2026, 9:15 AM ET

Top materiality 0.85

Event mix other_material ×6 · regulatory ×2 · leadership ×2

Sentiment 4 pos · 2 neg · 4 neu

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for CURX

Highest-materiality recent filing

Curanex Pharmaceuticals prices IPO of 3.75M shares at $4.00/share, gross $15M

August 26, 2025, 7:59 PM ET other material materiality 0.85 positive item 1.01 item 8.01 item 9.01

Gross proceeds $15M from 3.75M shares at $4.00/share; net proceeds ~$12.1M after underwriting discounts and expenses.
Shares expected to begin trading on Nasdaq (CURX) on Aug 26, 2025; close expected Aug 27, 2025.

Read filing →

May 14, 2026, 9:15 AM ET other material materiality 0.60 positive item 7.01 item 9.01

Curanex completes key Phyto-N milestones; plans Q4 2026 IND for ulcerative colitis

Completed GMP pilot-scale batch of Phyto-N in February 2026 to support IND-enabling studies.
May 7, 2026, 7:59 PM ET regulatory materiality 0.55 negative item 8.01

Nasdaq grants CURX additional 180 days until Nov 2, 2026 to meet $1 bid price

Received Nasdaq notice on Nov 5, 2025 for bid price below $1.00; initial 180-day period ended May 4, 2026.
April 2, 2026, 7:59 PM ET other material materiality 0.55 neutral item 7.01 item 9.01

Curanex expands drug pipeline to include cancer cachexia, a multi-billion-dollar market

Company adds cancer cachexia as a new core indication beyond its six existing programs (ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, gout).
March 6, 2026, 6:59 PM ET leadership materiality 0.50 neutral item 1.01 item 5.02 item 9.01

Curanex Pharmaceuticals formalizes CEO/COO agreements; base salaries $393,600 and $180,000

CEO Jun Liu: annual base salary $393,600, three-year term, plus $3,998/month auto lease.
January 5, 2026, 6:59 PM ET leadership materiality 0.55 neutral item 5.02 item 9.01

Curanex CFO Haiyan Yang resigns; Wanjun Zhang appointed effective Jan 1, 2026

Haiyan Yang resigned as CFO and Treasurer effective Dec 31, 2025; no disagreement cited.
November 6, 2025, 6:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

Curanex Pharmaceuticals receives Nasdaq bid price deficiency notice; 180-day cure period

Received Nasdaq notice on Nov 5, 2025 for bid price below $1.00 for 30 consecutive days.
September 29, 2025, 7:59 PM ET other material materiality 0.55 positive item 3.02 item 8.01 item 9.01 ◈ Equity Issuances

Curanex repays $408.5K in related-party loans, issues 28,312 shares for $200K

Issued 28,312 shares to Xiaohong Song for $200,000 under amended subscription agreement; shares are 0.1% of total outstanding.
September 12, 2025, 7:59 PM ET other material materiality 0.55 positive item 8.01 item 9.01

Curanex Pharma underwriters exercise full over-allotment; additional $2.25M raised

Over-allotment option exercised in full; 562,500 shares at $4.00, raising additional $2.25M.
August 27, 2025, 7:59 PM ET other material materiality 0.70 neutral item 8.01 item 9.01

Curanex Pharmaceuticals closes IPO of 3.75M shares at $4.00, raising $15M gross

Gross proceeds of $15M from IPO of 3,750,000 shares at $4.00 per share on firm commitment basis.
August 26, 2025, 7:59 PM ET other material materiality 0.85 positive item 1.01 item 8.01 item 9.01

Curanex Pharmaceuticals prices IPO of 3.75M shares at $4.00/share, gross $15M

Gross proceeds $15M from 3.75M shares at $4.00/share; net proceeds ~$12.1M after underwriting discounts and expenses.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.55 · Most common event other_material

4 positive 2 negative 4 neutral

source · CURX on sec.gov